AI-assisted mRNA cancer treatment succeeds in Phase 3 trial, cutting recurrence risk by 49%
abhiadesai · x · 2026-08-20
Moderna and Merck announced success in Phase 3 trials for an AI-assisted personalized mRNA cancer treatment. The technology sequences patient tumors and uses AI to identify mutations most likely to trigger an immune response, producing individualized mRNA therapies encoding up to 34 neoantigens.
Key Phase 2 Data:
- Recurrence-free survival: 68.8% (vs 49.1% with Keytruda alone).
- Risk of recurrence or death: Reduced by 49%.
- Risk of distant metastasis or death: Reduced by 59%.
This marks a milestone victory for AI applications in precision medicine and drug discovery.
More from Research
- Dev critiques compiling fast programs into slow neural nets: fun, but not useful — ctjlewis · 2026-10-16
- New paper uses revealed-preference methods to unpack why AI agents cooperate — brwilder · 2026-10-16
- Logit lens on a Beat Saber finetune reveals it reuses language grammar circuits — ctjlewis · 2026-10-16
- 128×128 record stands: how intermediate-work experiments foreshadowed reasoning models — ctjlewis · 2026-10-16
- TeamFusion: preference-based AI proxies debate to preserve minority views in team decisions — burkov · 2026-10-16
- MIT's C-GMT gives humanoid robots whole-body compliance without sacrificing motion tracking — MIT_CSAIL · 2026-10-16